Adjuvant tamoxifen and exemestane in early breast cancer team free
How can the answer be improved?
Exemestane in the adjuvant setting. A third study is in progress. Exemestane was approved in the US and European Union for the adjuvant treatment of postmenopausal women with endocrinesensitive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to exemestane for the completion of a total of 5 consecutive years of adjuvant hormonal therapy.
Jan 28, 2011 For many years, tamoxifen was the standard adjuvant endocrine therapy for women with postmenopausal breast cancer, resulting in a reduction of the odds of recurrence of breast cancer by 40 and death by 26 after 5 years. 1 The thirdgeneration aromatase exemestane, and letrozoleshowed better efficacy than did tamoxifen in patients with metastatic breast cancer, 2, 3, 4 and have shown efficacy in several adjuvant treatment
Tamoxifen has been shown to reduce the risk of recurrence of breast cancer by 40 and death by 26 compared to patients who did not receive this adjuvant treatment (additional treatments, including chemotherapy and hormone therapy, given after the primary therapy such as surgery to reduce the risk of recurrence).
The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial is a phase III, an openlabel randomized controlled trial that was originally designed to compare exemestane with tamoxifen in postmenopausal women with early breast cancer.
The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase 3 trial was conducted in hospitals in nine countries. Postmenopausal women (median age 64 years, range 3596) with breast cancer were randomly assigned in a 1: 1 ratio to openlabel exemestane (25 mg once a day, orally) alone or following tamoxifen (20 mg once a day, orally) for 5 years.
Rating: 4.92 / Views: 683